P4–366: ZT–1 for the symptomatic treatment of mild to moderate Alzheimer disease (AD): Preliminary results of a multicenter, randomised, double–blind, placebo and active controlled phase II study | Zendy

Tamchès Emmanuel | Zendy; Orgogozo Jean-Marc | Zendy; Wilkinson David | Zendy; Todorova Yancheva Stefka | Zendy; Gagiano Carlo | Zendy; Grosgurin Pierre | Zendy; Porchet Hervé | Zendy; Scalfaro Pietro | Zendy

Premium

P4–366: ZT–1 for the symptomatic treatment of mild to moderate Alzheimer disease (AD): Preliminary results of a multicenter, randomised, double–blind, placebo and active controlled phase II study

Author(s) -

Tamchès Emmanuel,

Orgogozo Jean-Marc,

Wilkinson David,

Todorova Yancheva Stefka,

Gagiano Carlo,

Grosgurin Pierre,

Porchet Hervé,

Scalfaro Pietro

Publication year - 2006

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2006.05.2107

Subject(s) - donepezil , placebo , medicine , adverse effect , acetylcholinesterase , dementia , clinical trial , phases of clinical research , gastroenterology , pharmacology , disease , pathology , chemistry , biochemistry , alternative medicine , enzyme

IL-1 peaked at the 2 hour after reperfusion and was significantly lower in the high CGE dosage (531.8 151.1 ) than that (687.6 116.9) in the model group (P 0.01), but not significantly different from IL-1ra group(574.6 56.7). The expression of CRF peaked at the 12 hour after reperfusion and was significantly lower in a high CGE dosage (401.1 76.8) than that (428.8 38.1) in the model group at the 12 hour following cerebral ischemia-reperfusion (P 0.01), but not significantly different from IL-1ra group (408.3 81.7). Conclusions: Such data suggest that CGE has the function of inhibiting up-adjusted expression of IL-1 and CRF protein following cerebral ischemia-reperfusion, act as IL-1ra preventing and treating neurons damage in hippocampus in rat with VaD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research